WSC 2023 | Targeting atrial cardiopathy for stroke prevention: unanswered questions

It is now widely recognized that atrial cardiopathy precedes atrial fibrillation, thereby increasing the risk of clot formation and the potential for strokes. David Tirschwell, MD, FAAN, University of Washington, Seattle, Washington, discusses the use of anticoagulation therapy to mitigate stroke risk in patients with atrial cardiopathy. It remains uncertain whether this form of therapy proves most efficacious in cases of severe atrial cardiopathy or when patients have progressed into atrial fibrillation. There is a need to clarify the severity and persistence of atrial fibrillation in which therapy is most effective. Considering these questions, further research is required to define the ideal criteria for initiating anticoagulation therapy. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.